<DOC>
	<DOCNO>NCT00102752</DOCNO>
	<brief_summary>The purpose study determine safety glufosfamide administer combination gemcitabine .</brief_summary>
	<brief_title>Study Safety Efficacy Glufosfamide Combination With Gemcitabine Cancer</brief_title>
	<detailed_description>This study , TH-CR-301 , Phase 1/2 study evaluate efficacy safety glufosfamide combination gemcitabine advance solid tumor first line treatment pancreatic cancer . Study Hypothesis : Glufosfamide combination gemcitabine may provide benefit survival patient advance solid tumor metastatic pancreatic cancer .</detailed_description>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Ifosfamide</mesh_term>
	<criteria>At least 18 year age Histologically cytologically confirm , locally advanced metastatic solid malignancy ; previously treat least one chemotherapy regimen advance metastatic disease effective standard treatment available OR Metastatic and/or locally advanced , inoperable pancreatic adenocarcinoma proven either histology ( surgical biopsy ) cytology ( CT endoscopicguided ) Measurable nonmeasurable disease RECIST criterion ( least one target nontarget lesion ) Recovered reversible toxicity prior therapy Karnofsky performance status ≥70 Women childbearing potential men use effective mean contraception entry study 6 month last dose Ability understand purpose risk study provide write informed consent . Prior chemotherapy metastatic/locally advanced pancreatic cancer Prior administration gemcitabine Radiation therapy within 28 day prior study start Hormonal therapy , biologic therapy , chemotherapy systemic antitumor therapy cancer within 21 day prior study start Symptomatic brain metastasis ( baseline CT scan require asymptomatic subject ) Active , clinically significant infection require antibiotic Known HIV positive active hepatitis B C History symptom cardiovascular disease ( NYHA Class 3 4 ) Other primary malignancy ( treat nonmelanoma skin cancer treat situ cancer ) within past 5 year Major surgery within 3 week start study treatment , without complete recovery Clinically significant abnormality laboratory test result ( include complete blood count , chemistry panel include electrolyte , urinalysis ) Hemoglobin &lt; 9 g/dL ( may receive transfusion erythropoietin maintain ) , ANC &lt; 1500/μL , Platelet count &lt; 100,000/μL , Total bilirubin &gt; 1.5 ×ULN , AST/ALT &gt; 2.5fold ULN ( &gt; 5fold ULN liver metastasis ) , Serum creatinine &gt; 2 mg/dL , Creatinine clearance &lt; 60 mL/min ( calculate ) Females pregnant breastfeed Participation investigational drug device study within 28 day first day dose study Concomitant disease condition could interfere conduct study Unwillingness inability comply study protocol reason</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2009</verification_date>
	<keyword>Pancreas</keyword>
	<keyword>Cancer</keyword>
	<keyword>Metastatic</keyword>
	<keyword>Glufosfamide</keyword>
	<keyword>Advanced</keyword>
	<keyword>Solid</keyword>
	<keyword>Tumor</keyword>
	<keyword>Advanced Solid Tumors</keyword>
	<keyword>Pancreatic Adenocarcinoma</keyword>
</DOC>